AR114419A1 - Compuestos y derivados de sulfonimidoilpurinona 7-sustituidos para el tratamiento y prevención del cáncer de hígado - Google Patents
Compuestos y derivados de sulfonimidoilpurinona 7-sustituidos para el tratamiento y prevención del cáncer de hígadoInfo
- Publication number
- AR114419A1 AR114419A1 ARP190100505A ARP190100505A AR114419A1 AR 114419 A1 AR114419 A1 AR 114419A1 AR P190100505 A ARP190100505 A AR P190100505A AR P190100505 A ARP190100505 A AR P190100505A AR 114419 A1 AR114419 A1 AR 114419A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- benzyl
- amino
- propylsulfonimidoyl
- carbonyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018077501 | 2018-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114419A1 true AR114419A1 (es) | 2020-09-02 |
Family
ID=65685310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100505A AR114419A1 (es) | 2018-02-28 | 2019-02-28 | Compuestos y derivados de sulfonimidoilpurinona 7-sustituidos para el tratamiento y prevención del cáncer de hígado |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3758707A1 (ja) |
| JP (1) | JP7089596B2 (ja) |
| KR (1) | KR20200128414A (ja) |
| CN (1) | CN111801100B (ja) |
| AR (1) | AR114419A1 (ja) |
| AU (1) | AU2019228654A1 (ja) |
| BR (1) | BR112020016509A2 (ja) |
| CA (1) | CA3091950A1 (ja) |
| CL (1) | CL2020002139A1 (ja) |
| CO (1) | CO2020010306A2 (ja) |
| IL (1) | IL276817A (ja) |
| MA (1) | MA52412A (ja) |
| MX (1) | MX2020008746A (ja) |
| PE (1) | PE20211456A1 (ja) |
| PH (1) | PH12020551343A1 (ja) |
| RU (1) | RU2020131012A (ja) |
| SG (1) | SG11202008291XA (ja) |
| TW (1) | TW202003518A (ja) |
| WO (1) | WO2019166432A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| KR102409595B1 (ko) | 2020-06-29 | 2022-06-17 | 한국과학기술연구원 | 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체 |
| CN112420196A (zh) * | 2020-11-20 | 2021-02-26 | 长沙市弘源心血管健康研究院 | 急性心肌梗死患者5年内生存率的预测方法和系统 |
| WO2024013205A1 (en) * | 2022-07-14 | 2024-01-18 | F. Hoffmann-La Roche Ag | Phosphorylpurinone compounds for the treatment of cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4189048B2 (ja) * | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| AU2009333559B2 (en) | 2008-12-09 | 2015-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
| SG175796A1 (en) * | 2009-05-21 | 2011-12-29 | Astrazeneca Ab | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases |
| EP2491035B1 (en) * | 2009-10-22 | 2017-08-30 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| US20110150836A1 (en) * | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| JP5848761B2 (ja) | 2010-06-24 | 2016-01-27 | アルカーメス ファーマ アイルランド リミテッド | Ｎｈ酸性化合物のプロドラッグ：エステル、カルボネート、カルバメートおよびホスホネートの誘導体 |
| BR112013002940A2 (pt) * | 2010-08-13 | 2019-09-24 | Baylor Res Institute | adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos |
| DK3294740T3 (da) * | 2015-05-08 | 2019-11-04 | H Hoffmann La Roche Ag | Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| SI3504210T1 (sl) | 2016-08-29 | 2021-08-31 | F. Hoffmann-La Roche Ag | 7-substituirane sulfonimidoilpurinonske spojine za zdravljenje virusne okužbe in zaščito pred njo |
| AU2017326400B2 (en) * | 2016-09-13 | 2023-03-30 | F. Hoffmann-La Roche Ag | Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor |
-
2019
- 2019-02-26 CN CN201980015912.7A patent/CN111801100B/zh active Active
- 2019-02-26 MA MA052412A patent/MA52412A/fr unknown
- 2019-02-26 SG SG11202008291XA patent/SG11202008291XA/en unknown
- 2019-02-26 AU AU2019228654A patent/AU2019228654A1/en not_active Abandoned
- 2019-02-26 EP EP19708981.6A patent/EP3758707A1/en active Pending
- 2019-02-26 CA CA3091950A patent/CA3091950A1/en active Pending
- 2019-02-26 WO PCT/EP2019/054729 patent/WO2019166432A1/en unknown
- 2019-02-26 KR KR1020207027935A patent/KR20200128414A/ko unknown
- 2019-02-26 RU RU2020131012A patent/RU2020131012A/ru unknown
- 2019-02-26 BR BR112020016509-3A patent/BR112020016509A2/pt not_active Application Discontinuation
- 2019-02-26 MX MX2020008746A patent/MX2020008746A/es unknown
- 2019-02-26 PE PE2020001228A patent/PE20211456A1/es unknown
- 2019-02-26 JP JP2020544794A patent/JP7089596B2/ja active Active
- 2019-02-27 TW TW108106752A patent/TW202003518A/zh unknown
- 2019-02-28 AR ARP190100505A patent/AR114419A1/es unknown
-
2020
- 2020-08-19 IL IL276817A patent/IL276817A/en unknown
- 2020-08-19 CL CL2020002139A patent/CL2020002139A1/es unknown
- 2020-08-21 CO CONC2020/0010306A patent/CO2020010306A2/es unknown
- 2020-08-27 PH PH12020551343A patent/PH12020551343A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020016509A2 (pt) | 2020-12-15 |
| RU2020131012A (ru) | 2022-03-28 |
| CN111801100A (zh) | 2020-10-20 |
| JP2021514972A (ja) | 2021-06-17 |
| TW202003518A (zh) | 2020-01-16 |
| PE20211456A1 (es) | 2021-08-05 |
| EP3758707A1 (en) | 2021-01-06 |
| MA52412A (fr) | 2021-06-02 |
| WO2019166432A1 (en) | 2019-09-06 |
| KR20200128414A (ko) | 2020-11-12 |
| AU2019228654A1 (en) | 2020-09-03 |
| CL2020002139A1 (es) | 2021-01-04 |
| SG11202008291XA (en) | 2020-09-29 |
| MX2020008746A (es) | 2020-09-28 |
| CO2020010306A2 (es) | 2020-08-31 |
| JP7089596B2 (ja) | 2022-06-22 |
| PH12020551343A1 (en) | 2021-06-21 |
| IL276817A (en) | 2020-10-29 |
| CN111801100B (zh) | 2023-10-24 |
| CA3091950A1 (en) | 2019-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114419A1 (es) | Compuestos y derivados de sulfonimidoilpurinona 7-sustituidos para el tratamiento y prevención del cáncer de hígado | |
| ECSP20067394A (es) | Inhibidores de cinasa dependientes de ciclina | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
| PE20200008A1 (es) | Isoquinolinas como inhibidores de hpk1 | |
| CO2021015698A2 (es) | Moduladores de thr-β y métodos de uso de estos | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| AR111295A1 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR088748A1 (es) | Macrociclos como inhibidores del factor xia | |
| CL2021002104A1 (es) | Compuestos, composiciones y métodos. | |
| CL2017002207A1 (es) | Inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
| CO2019000932A2 (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| PH12016501066A1 (en) | ROR GAMMA (ROYy) MODULATORS | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| AR119010A1 (es) | Compuestos, composiciones y métodos de uso | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
| AR100713A1 (es) | Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| AR117206A1 (es) | Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer | |
| AR122092A1 (es) | Inhibidores de diacilglicerol o-aciltransferasa 2 | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| CO2022004391A2 (es) | Derivados de 5-oxa-2–azaespiro[3.4]octano como agonistas de m4 | |
| AR121878A1 (es) | DERIVADOS DE BENZODIAZEPINA COMO PAM DE GABAA g1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |